Daneng Li, MD, of City of Hope, discusses dose-finding results from a phase I/II trial of tegavivint, a downstream Wnt/β-catenin inhibitor, in patients with advanced hepatocellular carcinoma (HCC) (Abstract 4015).
Xin Gao, MD, of Massachusetts General Hospital and Harvard Medical School, discusses initial results from the phase I EXCEED trial of LY4101174, a Nectin-4–targeting antibody-drug conjugate, for patients with advanced or metastatic urothelial carcinoma (Abstract 4517).
Misty Dawn Shields, MD, PhD, of Indiana University Melvin and Bren Simon Comprehensive Cancer Center, shares her perspective on two small cell lung cancer (SCLC) abstracts presented at this year’s meeting. The first focuses on a post hoc analysis of the phase III DeLLphi-304 trial (Abstract 8006), which looked at the intracranial efficacy of tarlatamab in the second line; the second evaluated concurrent thoracic radiotherapy, chemotherapy, and durvalumab in extensive-stage disease (Abstract LBA8005).
Brian M. Wolpin, MD, MPH, of Dana-Farber Cancer Institute, and Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, describe results from the phase III RASolute 302 trial, which evaluated the RAS(ON) muliselective inhibitor daraxonrasib in previously treated patients with metastatic pancreatic adenocarcinoma (Abstract LBA5).
François-Clément Bidard, MD, PhD, of Institut Curie, presents final progression-free survival 2 findings from the phase III SERENA-6 trial, which investigated the efficacy of camizestrant, a selective estrogen receptor degrader (SERD), vs continued aromatase inhibition in patients with advanced breast cancer with emergent ESR1 mutations. Earlier reports from the trial showed improved progression-free survival with the SERD (Abstract LBA1007).
Mali Barbi, MD, MS, of Northwell Health Cancer Institute Center for Women's Cancer, discusses durable survival benefits shown in the NRG-GY018 trial with pembrolizumab and the RUBY trial with dostarlimab for patients with mismatch repair–deficient (dMMR) endometrial cancer. In addition, B7-H4 antibody-drug conjugates such as puxitatug samrotecan are emerging as options for relapsed/metastatic disease.
